Skip to main content
Smart Investors Daily
SN

NASDAQ · SNY

Sanofi

Healthcare · Drug Manufacturers - General

$46.06

Down-$1.06 (-2.25%)

Updated Nov 20, 2026, 2:04 AM

SID Score

7.6/10

Composite research score

Smart Money

54/100

Neutral

Market cap
119.04B
P/E ratio
11.2
Dividend yield
4.80%
52-week range
$39.07 – $52.67
Volume
5.52M
Avg. volume
2.95M

Price performance · SNY

SNY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

SNY closed at $46.06 after 21 trading sessions, up 9.77% for the selected period.

Last close
$46.06
Period change
+9.77%
Period low
$41.60
Period high
$48.46
Daily close
View OHLC price history
SNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$46.43$46.61$44.93$46.065.52M
Nov 18, 2026$47.41$47.76$47.10$47.122.32M
Nov 17, 2026$47.54$47.96$47.50$47.531.77M
Nov 16, 2026$48.82$48.98$48.325$48.392.27M
Nov 13, 2026$48.51$48.655$48.21$48.371.68M
Nov 12, 2026$48.89$48.96$48.395$48.462.36M
Nov 11, 2026$47.61$48.46$47.522$48.432.44M
Nov 10, 2026$48.02$48.675$47.82$48.234.6M
Nov 9, 2026$47.99$48.4558$47.53$48.125.77M
Nov 6, 2026$45.63$47.16$45.58$47.043.9M
Nov 5, 2026$47.48$47.88$46.715$46.917.11M
Nov 4, 2026$46.85$47.49$46.4601$47.475.49M
Nov 3, 2026$45.53$45.70$45.055$45.335.63M
Nov 2, 2026$44.50$45.59$44.50$45.557.37M
Oct 30, 2026$44.82$45.30$44.2325$44.3415.1M
Oct 29, 2026$42.34$43.15$42.17$43.134.27M
Oct 28, 2026$41.83$42.33$41.63$42.242.91M
Oct 27, 2026$41.55$41.965$41.5324$41.892.45M
Oct 26, 2026$41.76$41.89$41.45$41.792.68M
Oct 23, 2026$41.70$41.75$41.33$41.602.01M
Oct 22, 2026$41.17$42.11$41.07$41.963.46M

Latest SNY news

The latest Smart Investors Daily articles mentioning SNY.

SNY research

Overview

Company profile and research snapshot.

Company profile

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$57.02
Implied upside
—
Analysts
14
SNY recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNNeutral—
Sep 21, 2026BERENBERGBuy—
Sep 8, 2026LEERINK PARTNERSOutperform—
Sep 4, 2026ODDO BHFBuy—
Aug 31, 2026INTESA SANPAOLO EQUITY RESEARCHBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 12, 2026

Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Listed on the Nasdaq Global Market under the ticker symbol “SCTX,” and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400 Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company’s epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027 Expanded strategic collaboration with Sanofi, providing access to the Company’s ELXR silencing technology and further validating its plat

Yahoo · Nov 12, 2026

Sanofi: Information concerning the total number of voting rights and shares - October 2026

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,415,546,786Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

Yahoo · Nov 10, 2026

Sanofi (SNY) Is Planning for a Patent Loss, Here’s Where Bulls Still See Opportunity

We just published a list of the 10 Stocks Analysts Just Upgraded and Sanofi (NASDAQ:SNY) ranked 8th on this list. Wall Street spent last Thursday reminding investors how quickly a favorite theme can turn. Worries that Democratic midterm wins could bring tighter rules for artificial intelligence and data centers sent technology stocks sharply lower. The […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.